The cannabis data analytics company announced that it is welcoming Marc Adelson, deputy chief legal officer at Teladoc Inc, to its board of directors.
Current board member David Danzinger was named the company’s chairman.
Adelson is the deputy chief legal officer at Teladoc Inc, a New York-based telemedicine company. He has spent nearly a decade with the health care technology firm, which connects healthcare professionals with patients.
“I have been a part of leading edge health care delivery and technology companies for quite some time, and I am thrilled to be able to lend my knowledge to CB2 Insights on the Board,” said Adelson. “I immediately recognized how critical CB2’s role is in understanding medical cannabis prescribing and efficacy and am excited to be a part of that evolution.”
New chairman Danzinger is the senior vice president, assurance and national leader, public companies at accounting firm MNP. He has been on CB2’s board since 2017.
“With the addition of Marc and now with David as our Chairman, we are proud of the diverse strength our Board is taking,” said Prad Sekar, CEO of CB2 Insights. “We are entering an exciting and pivotal time at CB2 as our clinical operations continue to expand and our data asset continues to grow in its value to a large number of stakeholders throughout the traditional health care industry.”
New nomination process
Toronto-based CB2 also announced it had adopted a bylaw to establish a framework for advance notice of nominations of directors by the CB2 shareholders.
The bylaw sets a procedure requiring advance notice by any shareholder who intends to nominate someone for election as a director and sets a deadline for shareholders to notify the company in writing ahead of nomination.
Shares of CB2 were trading at C$0.28 in Canada and US$0.21 in the US on Thursday morning.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas